Pelizzon David R sold $943K of KIDS (indirect holdings)

Pelizzon David R sold 38,300 indirectly-held shares of ORTHOPEDIATRICS CORP (KIDS) at an average of $24.63 ($24.28–$25.75, $0.94M total) across 3 trades over 2026-08-24 to 2026-08-26.

Original reporting
SEC EDGAR · Pelizzon David R
Published Aug 26, 2026, 10:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 11:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KIDS
Neutral
medium confidence
Mentioned
$KIDS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KIDSNeutralLow
01

Why it matters

The disclosed sale is modest and likely reflects personal financial planning rather than a change in company prospects.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential tax planning or liquidity needs for the insider; not necessarily a negative signal.

Relevance 5/10Novelty 4/10Timing: post‑market filing

Background

Form 4 filings disclose insider transactions; investors monitor large sales for signals.

Company-level read

Ticker impact

$KIDSNeutralMedium confidence
Context

Director and 10% owner sold 38,300 shares for $943K via open-market transactions.

Expected impact

Modest downward pressure; limited impact given the modest size relative to float.

Evidence & confidence

The sale is a routine Form 4 filing; amount is under $1M and represents a small fraction of holdings.

Market effects

Minimal; no broader sector impact.

None.

None.

Counterpoint

The sale could be unrelated to company outlook; may present a buying opportunity if fundamentals remain strong.

Key entities

  • Pelizzon David R

    10% owner of Orthopedics Corp who sold $943K of stock.

  • Orthopedics Corp

    Medical device company trading under ticker KIDS.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$KIDSMed

OrthoPediatrics Corp (KIDS) (Q3 2026) Earnings Call Highlights: Record Revenue and Raised Guidance

OrthoPediatrics Corp (KIDS) reported Q3 2026 revenue growth and raised guidance, despite increased sales expenses and gross margin pressure. The company expects Q4 revenue of roughly $69 million, with CEO David Bailey noting a conservative approach to guidance. International growth was tempered by Brazil headwinds, and the company remains unprofitable with a GAAP net loss per share of $0.25.

$KIDSMed

OrthoPediatrics Q3 Earnings Call Highlights

OrthoPediatrics (KIDS) reported Q3 revenue growth, with scoliosis revenue up 18% to $19.2M. The company surpassed 1,000 PNP tibial nail implantations and plans a full commercial release for PNP Retrograde in mid-2027. OPSB segment grew over 20%, with 60+ clinics. Gross margin remained at 74%, while GAAP net loss narrowed to $0.25 per share. The company raised full-year 2026 revenue guidance to $270M-$273M and expects positive free cash flow in 2027.

$KIDSHighAI 8/10

OrthoPediatrics (KIDS) Q3 2026 Earnings Call Transcript

OrthoPediatrics (KIDS) reported Q3 2026 revenue of $727M, up 19% YoY, and raised full-year guidance to $270M-$273M. Growth was driven by legacy products, implant demand, and international sales. The company highlighted progress in its innovation super cycle, with new products like 3P Hip, Traxeo, and VerteGlide contributing to performance. Adjusted EBITDA and free cash flow were record highs, with plans to maintain positive cash flow in 2027.